Skip to main content
Log in

Genotype-guided ticagrelor cost effective for stroke prevention in Asians

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Narasimhalu K, et al. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. Clinical Drug Investigation : 21 Sep 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00970-y

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genotype-guided ticagrelor cost effective for stroke prevention in Asians. PharmacoEcon Outcomes News 863, 16 (2020). https://doi.org/10.1007/s40274-020-7170-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7170-1

Navigation